Jim Cramer: Take a Look at Axovant Sciences (AXON)

NEW YORK (TheStreet) -- Shares of Axovant Sciences were down 8.43% to $27.38 in mid-morning trading Friday, shedding its gains of more than 99% from its initial public offering debut yesterday. Biotech firm Axovant priced 21 million shares at $15 per share on the New York Stock Exchange, raising $315 million and becoming the largest biotech IPO based on the amount raised, according to Renaissance Capital. TheStreet's Jim Cramer, Portfolio Manager of the Action Alerts PLUS Charitable Trust Portf...